Latest China News

Mesoblast has treated 350 patients in its pivotal Phase 3 trial for rexlemestrocel-L, targeting chronic low back pain linked to degenerative disc disease, setting the stage for top-line results in mid-2027.

American Rare Earths has partnered with Novex to tackle the critical oxide-to-metal bottleneck in the US rare earth supply chain, aiming to establish a fully domestic mine-to-magnet value chain from its Halleck Creek Project.

Avenira Ltd (ASX:AEV) is raising nearly $49 million through a heavily discounted three-for-two renounceable rights issue to finance the transition of its Wonarah Phosphate Project from development to production.

Stelar Metals has cleared all statutory hurdles and locked in an experienced driller to launch its maiden 3,500m RC drilling campaign at the Hill of Leaders Tungsten Project within weeks, targeting exceptionally high-grade tungsten mineralisation.

New Hope Group exceeded its FY26 coal production and sales guidance, driven by strong performances at Bengalla and New Acland mines, alongside a notable price uplift amid global supply tightness.

Dreadnought Resources has validated significant high-grade tungsten mineralisation at its Mangaroon and Mangaroon South projects in WA, with rock chip assays far exceeding typical global grades. Drilling at the key Nina target is slated for late 2026 or early 2027, while systematic mapping and sampling at Mangaroon South will start in September.

Euro Manganese has signed a non-binding term sheet with US battery materials producer 6K Energy, marking a critical step towards commercialising its Chvaletice manganese project with validated product quality and supportive financing terms.

Barramundi Limited’s portfolio delivered a 2.2% gross return in July, outpacing the S&P/ASX200 hedged benchmark, driven by strong performances in healthcare and financials alongside strategic portfolio adjustments.

The a2 Milk Company posted a 12.4% rise in FY26 revenue to NZ$1.975 billion, but net profit from continuing operations fell 5.8% amid supply chain disruptions in China. The company declared a $300 million special dividend and expects mid single-digit revenue growth in FY27.

Tian An Australia Limited posted a significant half-year loss of $3.9 million for June 2026, reversing prior profits as revenue plunged 86% due to lower sales at The Henley, Enfield. The company continues development across multiple residential projects while supported by a $230 million interest-free loan facility.

Proteomics International has achieved a key patent acceptance in Australia for its PromarkerEndo blood test, reinforcing its intellectual property portfolio and commercialisation strategy in a major healthcare market.

Stelar Metals has reported exceptional high-grade tungsten assays from Phase 2 sampling at Hill of Leaders, with grades up to 15.7% WO3 extending mineralisation beyond previous footprints. The company is gearing up for its first 3,000m reverse circulation drilling program amid strong market conditions for tungsten.